The University of Rhode Island, in collaboration with BayCare Health System in Florida and The Memory and Aging Program at Butler Hospital, an affiliate of The Warren Alpert Medical School of Brown University, is launching a clinical trial of retinal screening processes that could help clinicians detect Alzheimer's disease possibly two or more decades before patients develop life-altering clinical symptoms.
The five-year, $5 million Atlas of Retinal Imaging in Alzheimer's Study (ARIAS) is sponsored by BayCare Health System's Morton Plant Hospital and St. Anthony's Hospital and funded largely by Morton Plant Mease Health Care Foundation and St. Anthony's Hospital Foundation in Pinellas County, Florida.
Principal investigators for the study are Peter Snyder, Ph.D., URI vice president for research and economic development and professor of biomedical and pharmaceutical sciences, and Stuart Sinoff, M.D., who specializes in neuro-ophthalmology and is a medical director of Neurosciences for BayCare Health System's West Region in Pinellas County. According to the two researchers, the objective is to create a gold standard reference database of structural, anatomic and functional imaging of the retina to enable the identification and development of sensitive and reliable markers of early Alzheimer's disease and/or risk progression.
The problem now is that one of the central diagnostic tools for Alzheimer's disease, positron emission tomography (PET) scanning devices, which can detect amyloid protein plaques (a toxic protein that interferes with normal brain function), are expensive. While they can detect brain pathology related to Alzheimer's disease well before symptoms develop, the costs for such machines run into the millions and one test currently costs as much as $4,500. So, PET scans are often done after patients become symptomatic and when drug therapies may no longer be effective in slowing the disease in its earliest stages. Snyder also notes that a large portion of the world's population does not have access to PET scans.
When our study is completed, we want to make the technology available so that optometrists and ophthalmologists could screen for the retinal biomarkers we believe are associated with Alzheimer's disease and watch them over time. If clinicians see changes, they could refer their patients to specialists early on. We believe this could significantly lower the cost of testing. We may then identify more people in the very earliest stage of the disease, and our drug therapies are likely to be more effective at that point and before decades of slow disease progression." Peter Snyder, Ph.D., URI vice president for research and economic development and professor of biomedical and pharmaceutical sciences
Snyder and Sinoff are working with Stephen Salloway, M.D., director of Neurology and the Memory and Aging Program, Butler Hospital and Martin M. Zucker professor of psychiatry and human behavior, professor of neurology, Alpert Medical School of Brown University, who is a world-leading clinical trials expert in Alzheimer's disease, and Jessica Alber, Ph.D., URI assistant professor of research and cognitive neuroscientist, who completed her post-doctoral fellowship in the Department of Psychiatry and Human Behavior at the Alpert Medical School of Brown University with Salloway and Snyder. There are 14 other collaborators, including neuropsychologists, social workers, optometrists, nursing staff and students.
"We are very grateful to be working with some of the leading researchers in the field from BayCare, Butler Hospital and Brown University on this important study," Snyder said. "Drs. Sinoff, Salloway, Alber and I have already been publishing together in this area. I am honored that Dr. Salloway is leading our clinical site at Butler Hospital, and our work there will be tightly coordinated with the efforts on this study at BayCare's two flagship hospitals in Florida." Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology